2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1619-7089
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? ; volume:48 ; number:9 ; day:22 ; month:5 ; year:2021 ; pages:2668-2669 ; date:8.2021
European journal of nuclear medicine and molecular imaging ; 48, Heft 9 (22.5.2021), 2668-2669, 8.2021

Urheber
Herrmann, Ken
Kratochwil, Clemens
Fendler, Wolfgang P.
Eiber, Matthias
Hustinx, Roland
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00259-021-05409-w
URN
urn:nbn:de:101:1-2021101601312613143288
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:27 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

Ähnliche Objekte (12)

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Verbundene Objekte